Safety of the second dose of the ChAdOx1 nCoV‐19 vaccine in people with persistent anti–platelet factor 4 antibodies
Main Authors: | Noppacharn Uaprasert, Sasinipa Trithiphen, Autcharaporn Sukperm, Benjaporn Akkawat, Phandee Watanaboonyongcharoen, Rattaporn Vichitratchaneekorn, Thanisa Tongbai, Watsamon Jantarabenjakul, Leilani Paitoonpong, Ponlapat Rojnuckarin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Online Access: | https://doi.org/10.1002/rth2.12625 |
Similar Items
-
Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D‐dimer elevation in Thai people After ChAdOx1 nCoV‐19 vaccination
by: Noppacharn Uaprasert, et al.
Published: (2021-08-01) -
Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation
by: Thiti Asawapanumas, et al.
Published: (2022-01-01) -
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
by: Noppacharn Uaprasert, et al.
Published: (2022-12-01) -
Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition
by: Ngan Thi Tran, et al.
Published: (2020-05-01) -
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
by: Ogbe, A, et al.
Published: (2022)